Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29906590 | 0.78 | L3MBTL1 (0.53) | TDP1L3MBTL1MEN1ALDH1A1MAPT | |
| SCHEMBL14661214 | 0.78 | L3MBTL1 (0.53) | TDP1L3MBTL1MEN1ALDH1A1MAPT | |
| SCHEMBL30937027 | 0.75 | TDP1 (0.50) | TDP1L3MBTL1MEN1ALDH1A1MAPT | |
| SCHEMBL14661241 | 0.75 | TDP1 (0.50) | TDP1L3MBTL1MEN1ALDH1A1MAPT | |
| SCHEMBL8390310 | 0.75 | TDP1 (0.50) | TDP1L3MBTL1MEN1ALDH1A1MAPT | |
| SCHEMBL23846799 | 0.75 | L3MBTL1 (0.50) | TDP1L3MBTL1MEN1ALDH1A1MAPT | |
| SCHEMBL16555432 | 0.75 | TRPV4 (0.43) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL8297157 | 0.74 | HTR2A (0.34) | TDP1L3MBTL1 | |
| SCHEMBL11120954 | 0.74 | TRPV4 (0.42) | TDP1L3MBTL1MEN1ALDH1A1MAPT | |
| SCHEMBL14602399 | 0.74 | TRPV4 (0.42) | TDP1MEN1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787762-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | ARCUS BIOSCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787762-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | ARCUS BIOSCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2021188769-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787762-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | HIF1AN, HIF1A, EGLN2 | TDP1 3941/4885L3MBTL1 3919/4885MEN1 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.